Eli Lilly Raises 2026 Revenue Outlook After Strong Quarterly Earnings

Eli Lilly and Company reported second-quarter earnings and revenue that exceeded analyst expectations, primarily driven by surging demand for its diabetes treatment Mounjaro and weight loss drug Zepbound. The company posted adjusted earnings per share of $8.38, surpassing the $6.01 estimate, and generated $22.97 billion in revenue against an estimated $20.73 billion.

Growth was led by Mounjaro, which saw worldwide revenue rise 91% to $9.94 billion, and Zepbound, whose U.S. revenue increased 44% to $4.93 billion. The company also reported $98 million in sales for its newly approved obesity pill, Foundayo. Following these results, Eli Lilly raised its full-year 2026 revenue outlook to a range of $85 billion to $87 billion, up from the previous estimate of $82 billion to $85 billion.

CEO David A. Ricks expects lower prices to accelerate prescription volumes in the United States. These financial gains have supported a series of expansion efforts, including the acquisition of three vaccine makers in May and a psychedelics drugmaker in July. The company continues to compete with rival Novo Nordisk in the oral obesity drug market.